Your browser doesn't support javascript.
loading
HPV-18 E7 Interacts with Elk-1 Leading to Elevation of the Transcriptional Activity of Elk-1 in Cervical Cancer.
Go, Sung-Ho; Rho, Seung Bae; Yang, Dong-Wha; Kim, Boh-Ram; Lee, Chang Hoon; Lee, Seung-Hoon.
Afiliação
  • Go SH; Department of Life Science, Yong In University, Yongin 17092.
  • Rho SB; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408.
  • Yang DW; Department of Life Science, Yong In University, Yongin 17092.
  • Kim BR; College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea.
  • Lee CH; College of Pharmacy, Dongguk University, Goyang 10326, Republic of Korea.
  • Lee SH; Department of Life Science, Yong In University, Yongin 17092.
Biomol Ther (Seoul) ; 30(6): 593-602, 2022 Nov 01.
Article em En | MEDLINE | ID: mdl-36305294
The human papillomavirus (HPV)-18 E7 (E7) oncoprotein is a major transforming protein that is thought to be involved in the development of cervical cancer. It is well-known that E7 stimulates tumour development by inactivating pRb. However, this alone cannot explain the various characteristics acquired by HPV infection. Therefore, we examined other molecules that could help explain the acquired cancer properties during E7-induced cancer development. Using the yeast two-hybrid (Y2H) method, we found that the Elk-1 factor, which is crucial for cell proliferation, invasion, cell survival, anti-apoptotic activity, and cancer development, binds to the E7. By determining which part of E7 binds to which domain of Elk-1 using the Y2H method, it was found that CR2 and CR3 of the E7 and parts 1-206, including the ETS-DNA domain of Elk-1, interact with each other. As a result of their interaction, the transcriptional activity of Elk-1 was increased, thereby increasing the expression of target genes EGR-1, c-fos, and E2F. Additionally, the colony forming assay revealed that overexpression of Elk-1 and E7 promotes C33A cell proliferation. We expect that the discovery of a novel E7 function as an Elk-1 activator could help explain whether the E7 has novel oncogenic activities in addition to p53 inactivation. We also expect that it will offer new methods for developing improved strategies for cervical cancer treatment.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article